Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Javelin Pharmaceuticals, a developer of novel products for pain management, has announced that it will reduce its workforce by approximately 15%. The reduction is intended to reduce Javelin's cost structure.
Subscribe to our email newsletter
Martin Driscoll, CEO of Javelin Pharmaceuticals, said: “We have taken difficult, but necessary actions, to reduce fixed costs across the organization to conserve and extend valuable development dollars.
“Today’s organizational changes are being effected in support of our priorities to file high quality regulatory submissions in the US and the EU for Dyloject and Ereska in 2009 and consummate successful commercialization partnerships for our late stage acute pain care product portfolio.”